Sunshine Biopharma Warrant
SBFMW
3 hedge funds and large institutions have $3.34K invested in Sunshine Biopharma Warrant in 2024 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
898% more capital inflows, than outflows
Capital inflows: $569 | Capital outflows: $57
0.02% more ownership
Funds ownership: 0.25% → 0.27% (+0.02%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$569 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$30 |
| 2 |
Clear Street
New York
|
-$21 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6 |
SBFMW Hedge Fund Activity: Q1 2024 in Review
3 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma Warrant (SBFMW) for Q1 2024, worth a combined $3.34K — down 75% from $13.3K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SBFMW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, adding an estimated $569. The largest seller was Bank of America, exiting entirely with an estimated $30 sold.
- 3 institutional investors held Sunshine Biopharma Warrant (SBFMW) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $3.34K of Sunshine Biopharma Warrant stock for Q1 2024, down 75% quarter-over-quarter.
- 0 funds opened new Sunshine Biopharma Warrant positions in Q1 2024 and 1 closed out, a net change of -1 holder.
- The largest Sunshine Biopharma Warrant buyer in Q1 2024 was Citadel Advisors, an estimated $569 added.
- The largest Sunshine Biopharma Warrant seller in Q1 2024 was Bank of America, an estimated $30 sold.
Based on aggregated 13F filings for Q1 2024.